Following a breakthrough nod for Dexcom, CGMs may become a key part of hospital care.

As the early stages of the COVID-19 pandemic required action in many forms, continuous glucose monitors became an unexpected part of hospital care.

The FDA issued temporary guidance in April 2020 allowing for increased remote monitoring of hospital patients to limit contact with hospital staff and opportunities for COVID-19 transmission. That guidance extended to CGMs for the remote monitoring of people with diabetes.

Use of the technology in hospitals has always been of great intrigue for Scripps Whittier Diabetes Institute Corporate VP Dr. Athena Philis-Tsimikas, an adult endocrinologist who has been in practice for around three decades and has watched the development of CGMs since about 1999.

“[CGMs are] what we’ve been using to manage patients as I became more involved in having responsibility across our five hospitals and how we manage glucose within the hospital environment, setting targets and trying to get to targets,” Philis-Tsimikas told Drug Delivery Business News. “Looking at how quality metrics have changed over time in that environment, it occurred to me: Why can’t we use this great device and technology in the hospital environment?”

Get the full story at our sister site, Drug Delivery Business News.